Baxdrostat for hyperaldosteronism

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 6 Jun 2025: Trial registered, NCT07007793
  2. 7 Aug 2025: Trial started, NCT07007793

The trials

NCT04605549: A Study of CIN-107 in Adults With Primary Aldosteronism

State
Completed
Phase
Phase 2
People
15 taking part
Started
8 Mar 2021
Primary completion
28 Oct 2024
Arms
CIN-107 for dosing at 2, 4, or 8 mg (QD)
Results
Posted on the registry
Papers
doi:10.2215/cjn.0000000000000265
  1. 28 Oct 2020: Trial registered
  2. 8 Mar 2021: Trial started
  3. 28 Oct 2024: Trial completed
  4. 3 Mar 2026: Trial results posted

NCT07007793: Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

State
Under way
Phase
Phase 3
People
212 taking part
Started
7 Aug 2025
Primary completion
27 Jul 2027
Arms
Baxdrostat
Results
None posted
  1. 6 Jun 2025: Trial registered
  2. 7 Aug 2025: Trial started

NCT07800858: Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism

State
Not started
Phase
No phase
People
30 planned
Started
15 Sep 2026
Primary completion
31 May 2028
Arms
Baxdrostat
Results
None posted
  1. 2 Sep 2026: Trial registered

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Baxfendy, CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.